SCYNEXIS, Inc. Income (Loss) from Continuing Operations, Per Basic Share
SCYNEXIS, Inc. (SCYX) reported Income (Loss) from Continuing Operations, Per Basic Share of -$0.64 per share for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerBasicShare · last filed 2020-08-10
- SCYNEXIS, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2020-06-30 was -$0.64.
- SCYNEXIS, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2020-03-31 was -$0.07.
- SCYNEXIS, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2019-06-30 was -$1.58.
- SCYNEXIS, Inc. income (loss) from continuing operations, per basic share for the quarter ending 2019-03-31 was -$0.46.
- SCYNEXIS, Inc. income (loss) from continuing operations, per basic share for fiscal 2019 was -$0.96.
- SCYNEXIS, Inc. income (loss) from continuing operations, per basic share for fiscal 2018 was -$0.28.
- SCYNEXIS, Inc. income (loss) from continuing operations, per basic share for fiscal 2017 was -$0.94.
- SCYNEXIS, Inc. income (loss) from continuing operations, per basic share for fiscal 2016 was -$1.58.
| Period end | Income (Loss) from Continuing Operations, Per Basic Share 3 month | Income (Loss) from Continuing Operations, Per Basic Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 6 month | Income (Loss) from Continuing Operations, Per Basic Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Basic Share 9 month | Income (Loss) from Continuing Operations, Per Basic Share 12 month |
|---|---|---|---|---|---|---|
| 2020-06-30 | -$0.64 10-Q · filed 2020-08-10 | -$1.35 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | -$0.07 10-Q · filed 2020-05-11 | |||||
| 2019-12-31 | -$0.96 10-K · filed 2020-03-11 | |||||
| 2019-06-30 | -$1.58 10-Q · filed 2020-08-10 | -$0.16 10-Q · filed 2019-08-07 | -$6.10 10-Q · filed 2020-08-10 | -$0.61 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | -$0.46 10-Q · filed 2020-05-11 | |||||
| 2018-12-31 | -$0.28 10-K · filed 2020-03-11 | |||||
| 2018-06-30 | -$0.23 10-Q · filed 2019-08-07 | -$0.37 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | -$0.12 10-Q · filed 2019-05-08 | |||||
| 2017-12-31 | -$0.94 10-K · filed 2019-03-14 | |||||
| 2017-09-30 | -$0.31 10-Q · filed 2017-11-07 | -$0.67 10-Q · filed 2017-11-07 | ||||
| 2017-06-30 | -$0.16 10-Q · filed 2018-08-09 | -$0.35 10-Q · filed 2018-08-09 | ||||
| 2016-12-31 | -$1.58 10-K · filed 2018-03-13 | |||||
| 2016-09-30 | -$0.48 10-Q · filed 2017-11-07 | -$1.53 10-Q · filed 2017-11-07 | ||||
| 2016-06-30 | -$0.56 10-Q · filed 2017-08-08 | -$1.07 10-Q · filed 2017-08-08 | ||||
| 2016-03-31 | -$0.52 10-Q · filed 2016-05-09 | |||||
| 2015-12-31 | -$2.33 10-K · filed 2017-03-13 | |||||
| 2015-09-30 | -$0.54 10-Q · filed 2015-11-13 | -$1.72 10-Q · filed 2015-11-13 | ||||
| 2015-06-30 | -$0.53 10-Q · filed 2016-08-08 | -$1.20 10-Q · filed 2016-08-08 | ||||
| 2015-03-31 | -$0.70 10-Q · filed 2016-05-09 | |||||
| 2014-12-31 | -$1.28 10-K · filed 2017-03-13 | |||||
| 2014-09-30 | -$0.50 10-Q · filed 2015-11-13 | -$0.82 10-Q · filed 2015-11-13 | ||||
| 2014-06-30 | $0.27 10-Q · filed 2015-08-19 | -$0.19 10-Q · filed 2015-08-19 | ||||
| 2014-03-31 | -$4.75 8-K · filed 2015-10-30 | |||||
| 2013-12-31 | -$142.06 8-K · filed 2015-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |